Core Viewpoint - Rosen Law Firm is encouraging investors of aTyr Pharma, Inc. to secure legal counsel before the December 8, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - The class period for the aTyr Pharma securities class action is from January 16, 2025, to September 12, 2025 [2]. - Investors who purchased common stock during this period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by December 8, 2025 [4]. Group 2: Legal Representation - Investors are advised to choose qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - The Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [5]. Group 3: Case Allegations - The complaint alleges that aTyr Pharma provided misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [6]. - The lawsuit claims that when the true information became public, investors suffered damages as a result [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [1][3]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against aTyr, with a deadline of December 8, 2025, for investors to seek the role of lead plaintiff [1][5]. Group 2: Allegations Against aTyr - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about Efzofitimod, particularly regarding its ability to allow patients to taper off steroid usage [3]. - The EFZO-FIT study results indicated that efzofitimod did not show a significant change in mean daily oral corticosteroid dose at week 48, with a reduction of only 2.79 mg for the drug compared to 3.52 mg for placebo [4]. - Following the release of the study results, aTyr's stock plummeted by 83.25%, dropping from $6.03 to $1.01 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of aTyr Pharma, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who bought aTyr Pharma common stock between January 16, 2025, and September 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 8, 2025 [3][5]. - The complaint alleges that defendants made misleading statements regarding the efficacy of Efzofitimod, particularly its ability to allow patients to taper steroid usage completely, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of aTyr Pharma, Inc. to secure legal counsel before the December 8, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - The class period for the aTyr Pharma securities class action is from January 16, 2025, to September 12, 2025 [1]. - Investors who purchased aTyr Pharma common stock during this period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by December 8, 2025 [3]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Allegations - The complaint alleges that aTyr Pharma's defendants made misleading statements regarding the efficacy of the drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [5]. - The lawsuit claims that when the true information became public, investors suffered damages as a result of these misleading statements [5].

Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between November 7, 2024, and September 12, 2025 [1][2] - The lawsuit claims that aTyr made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage [2] - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a significant stock price drop of 83.2% from $6.03 to $1.02 per share [2] Case Details - The lawsuit seeks to recover losses for investors who were misled by the company's positive statements while concealing adverse facts about the drug's efficacy [2] - Following the announcement of disappointing study results, aTyr plans to engage with the FDA to determine the next steps [2] Next Steps for Investors - Investors who suffered losses during the relevant time frame have until December 8, 2025, to request to be appointed as lead plaintiff [3] - Participation in the class action does not require serving as a lead plaintiff, and there are no costs or obligations for class members [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - Rosen Law Firm is encouraging investors of aTyr Pharma, Inc. to secure legal counsel before the December 8, 2025 deadline for a class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - The class period for the aTyr Pharma common stock is defined as January 16, 2025, to September 12, 2025, inclusive [2]. - Investors who purchased shares during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by December 8, 2025 [4]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - The Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [5]. Group 3: Case Allegations - The complaint alleges that aTyr Pharma provided misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [6]. - The lawsuit claims that when the true information became public, investors suffered damages as a result [6].

Financial Position - The company reported an accumulated deficit of $592.2 million as of September 30, 2025, and expects to continue incurring net losses for the foreseeable future [86]. - As of September 30, 2025, the company had cash, cash equivalents, restricted cash, and available-for-sale investments totaling $92.9 million, sufficient to meet material cash requirements for at least one year [86]. - The company has material cash requirements primarily related to an operating lease and a financing lease for research and development equipment [96][98]. - The financing lease liabilities totaled $1.0 million as of September 30, 2025, with $1.5 million in cash collateral included in restricted cash [98]. Research and Development - The company’s lead therapeutic candidate, efzofitimod, is in clinical development for interstitial lung disease (ILD) and has received orphan drug designations from the FDA for sarcoidosis and systemic sclerosis [73][74]. - In a Phase 3 trial (EFZO-FIT) involving 268 patients, efzofitimod did not meet its primary endpoint of reducing mean daily oral corticosteroid dose at week 48, but showed clinically meaningful improvements in the King's Sarcoidosis Questionnaire score [76]. - The EFZO-CONNECT study is a Phase 2 trial evaluating efzofitimod in patients with systemic sclerosis-associated ILD, with interim data showing improvement in three out of four patients treated [78]. - The company expects research and development expenses to continue increasing, focusing on clinical development and manufacturing of efzofitimod and other potential therapeutics [103]. - Research and development expenses for Q3 2025 were $22.1 million, an increase of $7.3 million from $14.8 million in Q3 2024, primarily due to increased manufacturing costs [109]. - For the nine months ended September 30, 2025, research and development expenses totaled $49.3 million, an increase of $7.2 million from $42.1 million in the same period of 2024 [114]. - The increase in research and development expenses in Q3 2025 was mainly due to an $8.2 million rise in manufacturing costs for efzofitimod [109]. - Non-cash expenses in research and development increased by $0.1 million in Q3 2025, primarily due to higher stock-based compensation [109]. - The company anticipates fluctuations in both research and general administrative expenses based on the future direction of efzofitimod in pulmonary sarcoidosis [110][111]. Collaboration and Financing - The company has entered into a collaboration agreement with Kyorin for the development and commercialization of efzofitimod in Japan, generating $20.0 million in upfront and milestone payments to date [79][81]. - The Kyorin Agreement has generated $20.0 million in upfront and milestone payments, with potential additional payments of up to $155.0 million based on development and sales milestones in Japan [89][101]. - The company relies primarily on the Jefferies ATM Offering Program for financing, with stock price volatility impacting its ability to generate cash from financing activities [87]. - The Jefferies ATM Offering Program allows the company to sell up to $215.0 million in common stock, with $40.3 million net proceeds from 20,653,450 shares sold in 2024 and $66.4 million from 13,887,177 shares sold in 2025 at a weighted-average price of $4.94 per share [88][92]. - Net cash provided by financing activities increased significantly to $66.1 million in 2025 from $21.0 million in 2024, mainly due to proceeds from the Jefferies ATM Offering Program [92]. Revenue and Expenses - The company has not generated any revenues from product sales to date and anticipates significant commercialization expenses if marketing approval is obtained for product candidates [93]. - License and collaboration agreement revenues for Q3 2025 were $190,000, a decrease of $45,000 compared to Q3 2024 revenues of $235,000 [113]. - General and administrative expenses for Q3 2025 were $4.8 million, up from $3.3 million in Q3 2024, reflecting higher personnel-related costs and professional fees [111]. - General and administrative expenses for the nine months ended September 30, 2025 were $13.7 million, up from $10.2 million in 2024, driven by increased personnel and pre-commercialization costs [115]. - Other income (expense), net for Q3 2025 was $1.0 million, compared to $0.9 million in Q3 2024, attributed to higher cash balances [112]. - Other income, net for the nine months ended September 30, 2025 was $2.7 million, a decrease from $3.0 million in 2024, primarily due to lower interest rates [116].

Financial Performance - aTyr Pharma reported a consolidated net loss of $25.7 million for Q3 2025, compared to a net loss of $17.3 million in Q3 2024, reflecting an increase of 48% year-over-year[14] - Total revenues for Q3 2025 were $190,000, compared to $235,000 in Q3 2024, indicating a decrease of 19%[14] - General and administrative expenses for Q3 2025 were $4.8 million, compared to $3.3 million in Q3 2024, reflecting a 44% increase[14] - The total operating expenses for Q3 2025 were $26.9 million, up from $18.1 million in Q3 2024, marking a 48% increase[14] Research and Development - Research and development expenses for Q3 2025 were $22.1 million, up from $14.8 million in Q3 2024, representing a 49% increase[14] - The Phase 3 EFZO-FIT™ study did not meet its primary endpoint but showed clinical benefits for the 5.0 mg/kg efzofitimod group across multiple efficacy measures[7] - Enrollment in the Phase 2 EFZO-CONNECT™ study is expected to be completed in the first half of 2026, with promising interim data reported earlier[2] - The company presented results from the Phase 3 EFZO-FIT™ study at the European Respiratory Society Congress 2025, highlighting its significance in the field[7] Future Plans - aTyr Pharma plans to meet with the FDA in Q1 2026 to discuss the path forward for efzofitimod in pulmonary sarcoidosis[4] Cash Position - The company ended Q3 2025 with $92.9 million in cash, cash equivalents, restricted cash, and investments, an increase from $75.1 million at the end of 2024[16]

Core Insights - The company reported results from the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis, indicating that while the primary endpoint was not met, the therapy showed improvements in quality of life and reduced steroid use [3][4] - The company plans to meet with the FDA in the first quarter of 2026 to discuss the future development of efzofitimod based on the study results [3][4] - The company ended Q3 2025 with $92.9 million in cash and investments, reflecting a solid financial position [9][13] Clinical Development Updates - The Phase 3 EFZO-FIT™ study involved 268 patients and evaluated two dosages of efzofitimod, with clinical benefits observed in various efficacy parameters despite not meeting the primary endpoint [4][6] - The Phase 2 EFZO-CONNECT™ study is ongoing, targeting systemic sclerosis-related interstitial lung disease, with enrollment expected to complete in the first half of 2026 [4][6] Financial Performance - For Q3 2025, the company reported total revenues of $190,000, primarily from license and collaboration agreements, compared to $235,000 in the same period of 2024 [11] - Research and development expenses for Q3 2025 were $22.1 million, up from $14.8 million in Q3 2024, reflecting increased clinical trial costs [9][11] - The net loss for Q3 2025 was $25.7 million, compared to a net loss of $17.3 million in Q3 2024, indicating higher operational costs [11]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential securities law violations at aTyr Pharma, Inc. following the company's announcement of disappointing clinical trial results that led to a significant drop in stock price [2][4]. Company Overview - aTyr Pharma, Inc. is a biopharmaceutical company listed on NASDAQ under the ticker ATYR [2]. - The company recently reported that its EFZO-FIT study did not meet its primary endpoint, which was the change from baseline in mean daily oral corticosteroid dose at week 48 [3]. Market Reaction - Following the announcement of the failed study results, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share by the close of trading on September 15, 2025, representing a decline of approximately 83.2% in a single day [4].